VH-310 (previously XV-110) is an ultra-long-acting prodrug of cabotegravir expected to provide dosing intervals of once-every-six-months or longer. VH-310 is under development by Exavir’s partner, ViiV Healthcare, a subsidiary of GlaxoSmithKline, and currently in a Phase 1 clinical study. Exavir will receive milestones and royalties on sales of VH-310.

XV-122 is a long-acting prodrug of dolutegravir expected to provide therapeutic concentrations of DTG in up to once-every-fourth-month dosing intervals, and to be compatible with self-administration via auto-injector. Dolutegravir is the most widely prescribed antiretroviral medication globally, and used by millions of people living with HIV.

XV-207 is a long-acting prodrug of tenofovir expected to provide therapeutic exposure to the active metabolite of tenofovir, tenofovir-diphosphate, for the treatment of HIV, HBV, and HIV-HBV co-infection. XV-207 is under development as partner agent to XV-122 for a complete treatment regimen for HIV and HIV / HBV co-infection.